Novartis’ Kisqali bests AZ’ Faslodex in breast cancer trial
Adding Kisquali to Faslodex resulted in an almost 30% reduction in risk of death compared to Faslodex alone
Read More
Tag: Faslodex
NICE nod for breast cancer delay drug
Eli Lilly’s Verzenio has been recommended for use within the Cancer Drugs Fund by NICE.
Read More
Breast cancer patients barred from NHS access to Faslodex
The National Institute for Health and Care has issued final guidelines rejecting AstraZeneca’s Faslodex for certain patients with breast cancer.
Read More
EU, US approvals for Faslodex combinations
AstraZeneca’s Faslodex has been cleared on both sides of the Atlantic for use in combination with a CDK4/6 inhibitor.
Read More
CHMP backs one generic and six label extensions
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended just one generic medicine for approval at its October meeting.
Read More
NICE turns down AZ’ Faslodex for breast cancer
It is looking unlikely that AstraZeneca’s breast cancer drug Faslodex will be routinely funded on the NHS to delay growth of a specific type of breast cancer, after cost regulators concluded that its benefit over existing therapies has not been shown at this time.
Read More
EU OKs first-line use of AZ’ Faslodex
EU regulators are permitting the use of AstraZeneca’s breast cancer drug Faslodex at an earlier stage of the treatment pathway in patients with certain forms of the disease.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
